Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 6
2017 12
2018 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
A Novel Color Fluorescence Navigation System for Intraoperative Transcutaneous Lymphatic Mapping and Resection of Sentinel Lymph Nodes in Breast Cancer: Comparison with the Combination of Gamma Probe Scanning and Visible Dye Methods.
Hokimoto N, Sugimoto T, Namikawa T, Funakoshi T, Oki T, Ogawa M, Fukuhara H, Inoue K, Sato T, Hanazaki K. Hokimoto N, et al. Oncology. 2018;94(2):99-106. doi: 10.1159/000484050. Epub 2017 Nov 10. Oncology. 2018. PMID: 29131021
Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.
Aarts MJ, Vriens BE, de Boer M, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Tol J, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, van der Rijt CCD, Smilde TJ, van der Velden AW, Peer N, Tjan-Heijnen VCG. Aarts MJ, et al. Oncology. 2017;93(5):323-328. doi: 10.1159/000479067. Epub 2017 Aug 22. Oncology. 2017. PMID: 28848182
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K. Nishimura R, et al. Oncology. 2017;93(1):51-61. doi: 10.1159/000468521. Epub 2017 May 6. Oncology. 2017. PMID: 28478451
16 results